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Background: Acute otitis media (AOM) is an important cause for antibiotic prescription within the paedi-
atric population and Streptococcus pneumoniae is a major pathogen associated with AOM episodes. This
study aimed at analysing the influence of the heptavalent and 13-valent pneumococcal conjugate vacci-
nes (PCV7 and PCV13) on pneumococcal carriage and serotype distribution in AOM.
Methods: Nasopharyngeal swabs (NPS) and middle ear fluid (MEF) were collected within a Swiss surveil-
lance study of outpatients from all ages with AOM between 2004 and 2015, covering three vaccination
eras (pre-PCV7, PCV7 and PCV13). Samples were cultured for pneumococcal identification, and the asso-
ciation of vaccine era with pneumococcal carriage was investigated by logistic regression analysis adjust-
ing for sociodemographic factors.
Findings: In total, 3300 NPS and 620 MEF were included in this study. The number of samples from
patients with AOM dropped over vaccination eras and S. pneumoniae was less frequently isolated in
the PCV13 era as compared to the other two eras. The latest (PCV13) vaccination era was independently
associated with a reduced pneumococcal carriage within NPS (adjusted odds ratio 0.65, 95%-CI 0.45–
0.94). Investigating serotype epidemiology, vaccine serotypes decreased significantly after the conjugate
vaccine introductions with the exception of serotype 3. Within the non-PCV13 serotypes, a particular
increase of serogroups 11, 15 and 23 was observed in both NPS and MEF.
Conclusion: A substantial change in pneumococcal carriage and serotype epidemiology suggests an
impact of the conjugate vaccines on pneumococcal AOM in Switzerland.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Otitis media (OM) is one of the most frequent childhood infec-
tions, a main reason of paediatric doctors’ visits, and has been
described as one of the most common reasons for antibiotic
prescription in children [1]. OM refers to an inflammation of the
middle ear and comprises two main entities: acute OM (AOM)
and OM with effusion (OME) [2]. AOM is characterized by acute
onset of clinical symptoms of inflammation such as otalgia (ear
pain), fever and clinical signs of inflammation which includemiddle ear effusion, redness of the tympanic membrane or
perforation. OME on the other hand is defined as middle ear
effusion without signs or symptoms of an ear infection [2]. The
most frequently isolated bacterial pathogens in AOM are
Streptococcus pneumoniae and non-typeable Haemophilus influenzae
[3], and nasopharyngeal carriage is generally regarded as the
prerequisite leading to subsequent respiratory infections [4].
After the introduction of pneumococcal conjugate vaccines
(PCVs) into routine vaccine schedules, the heptavalent and
13-valent pneumococcal conjugate vaccines (PCV7 and PCV13,
respectively) induced significant changes in the epidemiology of
S. pneumoniae, both in disease and in carriage in many different
countries [5–8]. However, the influence of the polysaccharide
vaccines on pneumococcal otitis media remains uncertain as
A. Allemann et al. / Vaccine 35 (2017) 1946–1953 1947results of previous studies have been controversial [5,9–11]. A sys-
tematic review on the impact of pneumococcal conjugate vaccine
reported a 0–9% efficacy on all-cause AOM in randomized trials
whereas the efficacy was higher in nonrandomized trials
(17–23%) [12].
In Switzerland, PCV7 and PCV13 have been recommended and
reimbursed by health insurance plans since late 2006 (for all chil-
dren younger than two years) and 2011 (for all children younger
than five years), respectively [13]. Between 2008 and 2010 the
pneumococcal vaccine coverage had been estimated at
approximately 50% for two, and 37% for three doses at the age of
two years [13,14]. From 2011 to 2013 coverage increased to 79%
for two and 75% for three doses, respectively [13,14]. Finally, for
2014 and 2015 the coverage for three doses was 80% and 81%,
respectively.
In Switzerland AOM is monitored since 1998 within a prospec-
tive national surveillance system based on a network of sentinel
paediatricians and general practitioners treating outpatients with
AOM [15]. In addition, sentinel physicians were collecting
nasopharyngeal swabs (NPS) and middle ear fluid (MEF) allowing
the investigation of longitudinal changes in pneumococcal aetiol-
ogy and serotype epidemiology in patients with AOM. However,
these samples have not yet been comprehensively analysed, and
the impact of the conjugate vaccines on the role of S. pneumoniae
in AOM in Switzerland remained unknown.
Therefore, the overall aim of our study was to investigate
changes in pneumococcal carriage in patients with AOM and sero-
type distribution before and after the introductions of the pneumo-
coccal conjugate vaccines PCV7 and PCV13, and explore risk factors
for nasopharyngeal pneumococcal carriage during AOM. In more
detail, the objectives were (I) To describe changes in characteristics
of patients with AOM within the Swiss sentinel network over the
pre-PCV7, PCV7 and PCV13 eras. (II) To assess the association of
pneumococcal conjugate vaccine eras and pneumococcal carriage
within NPS, adjusted for confounding by demographic factors.
(III) To describe temporal variations of the pneumococcal serotype
distribution over pre-PCV7, PCV7 and PCV13 eras within NPS and
MEF.2. Material and methods
2.1. Study design, setting and participants
This retrospective analysis of surveillance data included outpa-
tients of any age with AOM between 2004 and 2015. Patients were
monitored within a Swiss nationwide prospective surveillance sys-
tem for various different diseases,which is ongoing since 1998 and
has been described in detail previously [15]. In brief, this network
is composed of a convenience sample of general practitioners (GP)
and paediatricians from all geographical regions of Switzerland.
The diagnosis of AOM episodes was established according to Cen-
ters for Disease Control and Prevention (CDC) definitions, and
patients were eligible to be enrolled repeatedly for each new epi-
sode of AOM [15].
Participating doctors seeing AOM patients were asked to sam-
ple the nasopharynx and/or provide a sample of the middle ear
fluid in case of spontaneous rupture for the investigation of the
presence of Streptococcus pneumoniae. Therefore, our study design
was cross-sectional (i.e., a series of cross-sectional samples for
each year). Patients of whom no NPS or MEF was available were
excluded from this study. This surveillance program is part of the
governmental public health surveillance and is therefore exempted
from approval by Institutional Review Boards. There has been no
ethical approval to perform tympanocentesis for routine
surveillance.2.2. Study outcomes
Pneumococcal carriage and the serotype epidemiology were
specified as the primary study outcomes. Pneumococcal carriage
was defined as the presence of S. pneumoniae detected by culture
from NPS or MEF. Serotypes/serogroups were categorized accord-
ing to their inclusion in the conjugated vaccines: PCV7 serotypes
(4, 6B, 9V, 14, 18C, 19F, 23F); PCV13 serotypes (1, 3, 4, 5, 6A, 6B,
7F, 9V, 14, 18C, 19A, 19F, 23F); additional PCV13 serotypes not
included in PCV7 (1, 3, 5, 6A, 7F, 19A; further referred to as ‘‘addi-
tional PCV13 serotypes”) and non-PCV13 serotypes (all other sero-
types detected in NPS or MEF).
2.3. Vaccination era and confounding demographic factors
As a measure of the Swiss population’s exposure to the conju-
gate vaccines PCV7 and PCV13 the study era was categorized based
on vaccine introduction: a pre-PCV7 era (2004–2006), PCV7 era
(2007–2010) and PCV13 era (2011–2014). To take into account a
possible change in demographic factors over time, which could
potentially be confounding the association of any PCV era with
pneumococcal carriage, we included age (categorized into 1 year,
2–4 years and 5–15 years) as the most important confounder, as it
is established to be a well-known risk factor for varying pneumo-
coccal carriage.
As further confounding factors we included gender, day care
attendance, vaccination status (at least one dose of either PCV7
or PCV13), antibiotic therapy within the last 8 weeks (for any indi-
cation), AOM history (i.e., no previous AOM versus 1 episodes in
the last 12 months) and geographical region. For the latter,
Switzerland territory was categorized into two regions: the
Eastern-Southern region including both the large German-
speaking and the much smaller Italian- and Romansh-speaking
regions, and the Western region (French speaking) region.
2.4. Data collection
NPS were collected using twisted wire rayon tipped applicators
(Copan Ventury Transystem; Copan, Italy), and MEF were obtained
using the same or cotton tip swabs. As for the latter, the time of
collection of the samples after spontaneous perforation was not
recorded. With each sample, practitioners submitted a standard-
ized questionnaire containing patient information (age, gender,
vaccination statement, preceding antibiotic therapy, day care
attendance, AOM history (number of otitis media episodes within
the last 12 months) and place of residence).
After collection, samples of NPS and MEF were sent to the Swiss
pneumococcal reference laboratory for culture detection of S. pneu-
moniae. The presence of S. pneumoniae in MEF and NPS was
detected and confirmed by culture, using alpha hemolysis mor-
phology on blood agar plates and optochin sensitivity. Serotypes
of all Streptococcus pneumoniae isolates were determined by Quel-
lung reaction using antiserum from the Statens Serum Institute
(Copenhagen, Denmark).
2.5. Statistical analysis
Variations in the number of NPS, pneumococcal carriage in NPS
and MEF, and S. pneumoniae serotypes in both NPS and MEF over
the pre-PCV7, PCV7 and PCV13 era were compared with Chi-
square tests for trend.
The association of vaccine era with pneumococcal carriage was
analysed using logistic regression, adjusting for potential con-
founding by age, gender, day care attendance, vaccination status,
prior antibiotic therapy, AOM history and geographical region.
Missing values for PCV13 vaccinations were assumed to be non-
1948 A. Allemann et al. / Vaccine 35 (2017) 1946–1953vaccinated in the eras prior to the respective PCV7 or PCV13
introduction.
Statistical significance was claimed at an alpha level of 0.05
without adjustment for multiple hypothesis testing. All statistical
analyses were performed using the software R (version 3.1.3,
2015, http://www.R-project.org) and Graph Pad Prism.3. Results
3.1. Characteristics of NPS from AOM patients
In total, the general practitioners and paediatricians from the
Swiss Sentinella Network collected 3300 NPS from patients with
AOM between 2004 and 2015. Patients with AOM were mostly
children and about a third of the patients from which NPS were
received were less than 2 years old (Table 1). However, numbers
of the young (1 year and 2–4 years of age) were higher in the
pre-PCV7 as compared to the PCV13 era. In contrast, an increased
proportion of patients with AOM of >15 years of age was identified
for the PCV13 era (Table 1). Overall, the median age of patients
with AOM increased from 4 to 5 and 12 years, in the pre PCV7,
PCV7 and PCV13 era, respectively. There was a slightly higher
number of NPS collected from patients from the Eastern-
Southern region within the PCV13 as compared to the pre-PCV7Table 1
Characteristics of NPS from patients with acute otitis media, 2004–2015.
Pre-PCV7 era: 2004–2006
N %
Total number of NPSa 1588
Age
1 years 522 32.9
2–4 years 450 28.3
5–15 years 433 27.3
>15 years 176 11.1
NA 7 0.4
Day care visits
Yes 383 24.1
No 1105 69.6
NA 100 6.3
Region
East 938 59.1
West 649 40.9
NA 1 0.1
Gender
Female 732 46.1
Male 851 53.6
NA 5 0.3
Vaccination status
PCV7 Yesb 62 3.9
No 1437 90.5
NA 89 5.6
PCV13c Yesb 0 0.0
No 1588 100.0
NA 0 0.0
Antibiotics during the last 8 weeks
No 1328 83.6
Yes 235 14.8
NA 25 1.6
AOM history during the last 12 months
No 929 58.5
1 previous episode 529 33.3
NA 130 8.2
NA; Not available (missing): PCV; pneumococcal conjugate vaccine: PCV7, 7-valent pne
a Indicated are all study participants who provided a nasopharyngeal swab (NPS); Sam
included NPS from 2892 different patients.
b Indicates at least one dose of PCV7 or PCV13, respectively.
c In the eras prior PCV13 introduction (2004–2010), patients were assumed to be nonera. The distribution of gender, preceding antibiotic therapy, and
AOM history was similar for all three eras (Table 1).
However, a considerable decrease of samples received from
young patients with AOM in the more recent years was observed
(Supplementary Table 1), despite that the numbers of general prac-
titioners and paediatricians sending samples did not change sub-
stantially over the years (data not shown). This decrease was
seen in the age groups (1 year, p = 0.025; 2–4 years, p < 0.001
and 5–15 years, p < 0.001; Supplementary Table 1). In contrast,
an increase of samples was observed for patients >15 years of
age (p < 0.001). Therefore, this indicates that AOM was less often
diagnosed in the more recent years for the ages 0–15 years within
our Network.3.2. Variation of pneumococcal carriage within NPS over the vaccine
eras
From a total of 3300 NPS, S. pneumoniae was detected in 1525
(46%) of NPS (Table 2). Overall nasopharyngeal pneumococcal car-
riage declined from 50% in the pre-PCV7 and 49% in the PCV7 era to
36% in the PCV13 era (Table 2).
Univariate and multivariate logistic regression was subse-
quently performed to identify demographic and individual risk fac-
tors associated with pneumococcal carriage (Table 2). The adjustedPCV7 era: 2007–2010 PCV13 era: 2011–2015
N % N %
961 751
343 35.7 203 27.0
248 25.8 139 18.5
204 21.2 156 20.8
165 17.2 250 33.3
1 0.1 3 0.4
283 29.4 196 26.1
603 62.7 488 65.0
75 7.8 67 9.0
539 56.1 526 70.0
422 43.9 222 29.6
0 3 0.4
417 43.4 364 48.5
536 55.8 373 49.7
8 0.8 14 1.9
408 42.4 186 24.8
464 48.3 325 43.2
89 9.3 240 32.0
0 0.0 202 26.9
961 100.0 268 35.7
0 0.0 281 37.4
749 77.9 595 79.4
158 16.4 108 14.4
54 5.6 47 6.3
524 54.5 440 58.6
319 33.2 218 29.0
118 12.3 93 12.4
umococcal conjugate vaccine: PCV13, 13-valent pneumococcal conjugate vaccine.
ples from subsequent AOM episodes per patient were included. In total, this study
-vaccinated with PCV13.
Table 2
Risk factors for pneumococcal carriage within nasopharyngeal swabs.
Demographic characteristics Number of Swabs Pneumococcal carriage
N % n % OR 95% CI aOR 95% CI
Total swabs 3300 1525 46.2
Time
Pre-PCV7 era: 2004–2006 1588 48.1 788 49.6 REFa REF a
PCV7 era: 2007–2010 961 29.1 468 48.7 0.96 (0.82–1.13) 1.09 (0.87–1.37)
PCV13 era: 2011–2015 751 22.8 269 35.8 0.57 (0.47–0.68) 0.65 (0.45–0.94)
Age (years)
1 1068 32.4 611 57.2 REFa REF a
2–4 837 25.4 473 56.5 0.97 (0.81–1.17) 0.94 (0.76–1.18)
5–15 793 24.0 331 41.7 0.54 (0.44–0.64) 0.51 (0.40–0.65)
>15 591 17.9 108 18.3 0.17 (0.13–0.22) 0.18 (0.12–0.25)
Region
East 2003 60.7 833 41.6 REFa REF a
West 1293 39.2 692 53.5 1.62 (1.40–1.86) 1.16 (0.96–1.39)
Gender
Female 1513 45.8 680 44.9 REFa REF a
Male 1760 53.3 832 47.3 1.10 (0.96–1.26) 1.04 (0.87–1.23)
Day care attendance
No 2196 66.5 944 43.0 REFa REF a
Yes 862 26.1 488 56.6 1.73 (1.48–2.03) 1.33 (1.08–1.63)
Vaccination type
PCV7 No 2226 67.5 1006 45.2 REFa REF a
Yesb 656 19.9 363 55.3 1.50 (1.26–1.79) 0.76 (0.58–1.00)
PCV13c No 2817c 85.4 1325c 47.0 REFa REF a
Yesb 202 6.1 99 49.0 1.08 (0.81–1.44) 1.14 (0.61–2.03)
Antibiotics during the last 8 weeks
No 2673 81.0 1233 46.1 REFa REF a
Yes 501 15.2 229 45.7 0.98 (0.81–1.19) 0.68 (0.53–0.88)
AOM history during the last 12 months
No 1893 57.4 843 44.5 REFa REF a
1 previous episode 1066 32.3 530 49.7 1.23 (1.05–1.43) 0.88 (0.72–1.08)
Abbreviations: aOR: adjusted Odds ratio; 95% CI: 95% confidence intervals; AOM: acute otitis media; PCV7 and PCV13: 7- and 13-valent pneumococcal conjugate vaccine.
Confidence intervals that do not overlap the null value of OR = 1 are indicated in bold.
a REF, reference group for the regression analysis.
b Indicates at least one dose of PCV7 or PCV13, respectively.
c In the eras prior PCV13 introduction (2004–2010), we assumed patients were non-vaccinated with PCV13.
A. Allemann et al. / Vaccine 35 (2017) 1946–1953 1949model provided strong evidence for a reduction in S. pneumoniae
carriage during the PCV13 era (adjusted odds ratio (aOR) 0.65,
95% confidence interval (CI) 0.45–0.94; Table 2). Older children
and adults were less likely to be pneumococcal carriers than
younger patients (Table 2). Preceding antibiotic therapy was asso-
ciated with a significant decrease of pneumococcal carriage in our
adjusted model (OR 0.68, CI 0.53–0.88). An association of pneumo-
coccal carriage with region and AOM history observed in univariate
logistic regression could be explained by confounding factors
included in our adjusted model. However, as for AOM history, if
patients with one or more previous episodes during the last
12 months are excluded from the model, the pneumococcal car-
riage is still significantly reduced in the PCV13 era (data not
shown).3.3. Variation of the serotype epidemiology within NPS over the
vaccine eras
While PCV7 serotypes within pneumococcal isolates from NPS
dropped from 53.2% in the pre-PCV7 era to only 10.0% in the
PCV13 era, the number of non-PCV13 serotypes increased substan-
tially (Table 3 and Fig. 1). Compared to the pre-PCV7 era, additional
PCV13 serotypes within pneumococcal isolates first increased in
the PCV7 era, followed by a decrease in the PCV13 era. These find-
ings were consistent over all age groups.
In total, twenty-two serotypes/serogroups with an overall pro-
portion 1% were detected (Supplementary Table 2). Scrutinizingthe individual serotypes/serogroups revealed that all PCV13 sero-
types decreased, with the exception of serotype 3 for which pro-
portions of total pneumococcal isolates increased from 8.5% in
2004 to 11.1% in 2015 (Chi square test for trend; p = 0.013; Fig. 1A).
The highest proportion of serotype 3 was recorded in 2013 with
27.5%. However, in the PCV13 era, serotype 3 was less frequently
isolated within the very young (1 year) as compared to older chil-
dren (5–15 years) (Supplementary Table 3). As for serotype 19A,
this serotype increased in the PCV7 but subsequently decreased
significantly in the PCV13 era (Chi square test for trend;
p = 0.001; Fig. 1A).
The proportions of non-PCV13 serotypes increased from 26.1%
in 2004 to 85.2% in 2015 (Chi square test for trend; p < 0.001,
Fig. 1B). Serogroups 11, 15 and 23 (excluding serotype 23F) were
the most frequent emerging non-PCV13 serotypes (Fig. 1B). Similar
findings were discovered if PCV7, additional PCV13, and (total)
PCV13 serotypes were analysed stratified by age groups within
the three different eras (Table 3).3.4. Pneumococcal isolation of MEF from patients with AOM
Overall, 620 MEF were received of which 190, 180 and 250 MEF
were collected in the Pre-PCV7, PCV7 and PCV13 era, respectively
(Supplementary Table 4). As for the AOM history of these samples,
67 (35.3%), 63 (35.0%), and 95 (38.0%) were received from patients
who had one or more previous otitis media episodes during the last
12 months.
Table 3
Pneumococcal culture results of nasopharyngeal swabs (NPS) from patients with acute otitis media.
Pre-PCV7 era: 2004–2006 PCV7 era: 2007–2010 PCV13 era: 2011–2015 Χ2 test for trend
N % N % N %
Total isolates 788 100.0 468 100.0 269 100.0
PCV7 isolates 419 53.2 130 27.8 27 10.0 <0.0001
PCV13-7 isolates 191 24.2 169 36.1 85 31.6 0.0008
Non-PCV13 isolates 178 22.6 169 36.1 157 58.4 <0.0001
Per age group
1 year of age
Total isolates 314 100.0 188 100.0 109 100.0
PCV7 isolates 173 55.1 49 26.1 11 10.1 <0.0001
PCV13-7 isolates 67 21.3 65 34.6 24 22.0 0.3
Non-PCV13 isolates 74 23.6 74 39.4 74 67.9 <0.0001
2–4 years of age
Total isolates 251 100.0 145 100.0 77 100.0
PCV7 isolates 146 58.2 43 29.7 7 9.1 <0.0001
PCV13-7 isolates 48 19.1 51 35.2 22 28.6 0.009
Non-PCV13 isolates 57 22.7 51 35.2 48 62.3 <0.0001
5–15 years of age
Total isolates 189 100.0 95 100.0 47 100.0
PCV7 isolates 85 45.0 29 30.5 6 12.8 <0.0001
PCV13-7 isolates 63 33.3 38 40.0 25 53.2 0.01
Non-PCV13 isolates 41 21.7 28 29.5 16 34.0 0.05
>15 years of age
Total isolates 33 100.0 40 100.0 35 100.0
PCV7 isolates 15 45.5 9 22.5 3 8.6 0.004
PCV13-7 isolates 13 39.4 15 37.5 14 40.0 0.96
Non-PCV13 isolates 5 15.2 16 40.0 18 51.4 0.002
Abbreviations: PCV7, 7-valent pneumococcal conjugate vaccine: PCV13, 13-valent pneumococcal conjugate vaccine.
PCV7 isolates include the isolates with the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
PCV13-7 isolates include the isolates with the serotypes 1, 3, 5, 6A, 7F, 19A.
PCV13 isolates include the isolates with the serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
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Fig. 1. Variation of pneumococcal serotypes isolated from nasopharyngeal swabs over vaccination eras. Indicated are in (A) the PCV7 (7-valent pneumococcal conjugate
vaccine) and PCV13 (13-valent pneumococcal conjugate vaccine) serotypes. Furthermore, serotype 19A and serotype 3 and non-PCV7 but PCV13 serotypes excluding
serotypes 3 and 19A (serotypes 1, 5, 6A, 7F) are illustrated. (B) Non-PCV13 serogroups/serogroups are also illustrated and the most frequent are shown individually.
Serogroup 23 does not include serotype 23F. Data is plotted for each year and the introductions of the vaccines (PCV7 and PCV13) are indicated. Significant p-values (Chi
square test for trend) are shown. PCV7 isolates include the isolates with the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. PCV13-PCV7-serotype19A-serotype3 isolates include
the serotypes 1, 5, 6A, 7F.
1950 A. Allemann et al. / Vaccine 35 (2017) 1946–1953Within the collection of 620 MEF 146 (21.2%) were pneumococ-
cal culture positive. A significantly decreased pneumococcal car-
riage was observed in the PCV13 era (Supplementary Table 4).
However, no significant trend for pneumococcal carriage was
detected if stratified according to every age category (data not
shown). Similar as for the NPS, PCV7 and non-PCV13 serotypes
were less and more often isolated in the PCV13 era as compared
to the pre-PCV7 era, respectively (Table 4). Analysing individual
serotypes, serotype 3 was detected most frequently within each
of the three eras (Pre-PCV7, during the PCV7 and PCV13 era;
Fig. 2A). However, investigating individual non-PCV13 serotypes,serogroups 11, 15 and 23 (excluding serotype 23F) were the most
frequent within both MEF and NPS (Figs. 1B and 2B).
4. Discussion
This study reports the findings from a Swiss prospective surveil-
lance system for S. pneumoniae including patients with AOM
between 2004 and 2015, spanning over three major time periods
defined by the introductions of PCV7 (2007) and PCV13 (2011).
We found a decrease of NPS from patients with AOM in the more
recent years despite the number of physicians sending samples
Table 4
Pneumococcal culture results of middle ear fluids (MEF) from patients with acute otitis media.
Pre-PCV7 era: 2004–2006 PCV7 era: 2007–2010 PCV13 era 2011–2015 Χ2 test for trend
N % N % N %
Total isolates 46 100.0 57 100.0 43 100.0
PCV7 isolates 21 45.7 12 21.1 7 16.3 0.002
PCV13-7 isolates 23 50.0 33 57.9 25 58.1 0.5
Non-PCV13 isolates 2 4.3 12 21.1 11 25.6 0.02
Per age group
1 year of age
Total isolates 17 100.0 20 100.0 16 100.0
PCV7 isolates 14 82.4 6 30.0 5 31.3 0.003
PCV13-7 isolates 3 17.6 9 45.0 8 50.0 0.05
Non-PCV13 isolates 0 0.0 5 25.0 3 18.8 0.1
2–4 years of age
Total isolates 8 100.0 16 100.0 8 100.0
PCV7 isolates 3 37.5 5 31.3 2 25.0 0.6
PCV13-7 isolates 4 50.0 9 56.3 4 50.0 1
Non-PCV13 isolates 1 12.5 2 12.5 2 25.0 0.5
5–15 years of age
Total isolates 18 100.0 13 100.0 15 100.0
PCV7 isolates 4 22.2 1 7.7 0 0.0 0.04
PCV13-7 isolates 13 72.2 10 76.9 10 66.7 0.7
Non-PCV13 isolates 1 5.6 2 15.4 5 33.3 0.04
>15 years of age
Total isolates 3 100.0 8 100.0 4 100.0
PCV7 isolates 0 0.0 0 0.0 0 0.0 NA
PCV13-7 isolates 3 100.0 5 62.5 3 75.0 0.53
Non-PCV13 isolates 0 0.0 3 37.5 1 25.0 0.53
Abbreviations: PCV7, 7-valent pneumococcal conjugate vaccine: PCV13, 13-valent pneumococcal conjugate vaccine: NA, not available.
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Fig. 2. Variation of pneumococcal serotypes over vaccination era within middle ear fluids (MEF). Indicated are in (A) the PCV7 (7-valent pneumococcal conjugate vaccine) and
PCV13 (13-valent pneumococcal conjugate vaccine) serotypes. Furthermore, serotypes 19A and 3 as well as non-PCV7 but PCV13 serotypes excluding serotypes 3 and 19A
(serotypes 1, 5, 6A, 7F) are illustrated. Data is plotted according to vaccine era i.e. pre-PCV7 (2004–2006), PCV7 (2007–2010) and PCV13 era (2011–2015). Non-PCV13, (B)
serogroups/serogroups are also plotted and the most frequent are shown individually. Serogroup 23 does not include serotype 23F. Significant p-values (Chi square test of
trend) are indicated. PCV7 isolates include the isolates with the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. PCV13-PCV7-serotype19A-serotype3 isolates include the serotypes
1, 5, 6A, 7F.
A. Allemann et al. / Vaccine 35 (2017) 1946–1953 1951remained more or less constant. Pneumococcal nasopharyngeal
carriage decreased after vaccine introduction, and a decrease of S.
pneumoniae within MEF of patients with AOM after PCV13 intro-
duction was observed. Finally, a decrease of vaccine serotypes after
PCV introduction and a corresponding increase of non-vaccine ser-
otypes were noted.
Within this study we were not able to directly calculate inci-
dence numbers from patients with AOM which is a major limita-
tion but the identified decrease in the number of NPS from
patients with AOM might be indeed due to a lower incidence of
AOM in Switzerland in recent years. In addition, the median age
of AOM patients increased during the more recent years, a charac-
teristic often observed when an effective vaccine is introduced in
the youngest of the population. Therefore, a drop of AOM incidence
after vaccine introduction in young patients can be hypothesized[16,17]. However, we did not investigate important factors
potentially influencing AOM incidents like changes in the patient
or family healthcare seeking behavior though this may probably
not have changed as health insurance is mandatory and health care
services, including GP or paediatrician visits, are reimbursed. In
addition, we did not analyze adherence of GPs towards the national
AOM prescription guidelines.
A decline in AOM incidence would be consistent with reports
from other countries: A recent study from England and Wales
revealed an incidence of otitis media of 204.4 episodes per 1000
person-years (95% CI, 201.8–207.0) in <2 year-olds and 180.6 epi-
sodes/1000 (95% CI, 179.1–182.2) in 2–4 year-olds [18]. This data
was derived from a primary care electronic healthcare database.
In addition, Wau et al. discovered a decline in the number of
AOM incidence after introductions of both, PCV7 and PCV13 [18].
1952 A. Allemann et al. / Vaccine 35 (2017) 1946–1953Within our study, we specifically analysed pneumococcal car-
riage data of NPS, allowing the investigation of the associations
between the pneumococcal conjugate vaccines PCV7 and PCV13
and pneumococcal carriage. In France, in a study using a design
very similar to ours, PCV13 but not PCV7 had a strong impact on
pneumococcal carriage during AOM [19]. Overall, pneumococcal
carriage was reduced from 71.2% to 56.2% from 2001 to 2014 in
the French study (p < 0.001). Similarly, no effect of PCV7 on pneu-
mococcal carriage has been identified in Germany [20]. Within our
study, the relative trends were found to be comparable. Interest-
ingly, no clear effect of PCVs on pneumococcal carriage was identi-
fied within healthy individuals in England [21].
As for the changing serotype epidemiology within NPS, we
detected a near elimination of PCV7 serotypes which is common
in other settings, too [22–24]. Regarding the epidemiology of the
additional five PCV13 serotypes, there was also a decrease, how-
ever less pronounced, which may be due to the fact that PCV13
has been introduced more recently as compared to PCV7. While
serotype 3 (included in PCV13) persisted even in the PCV13 era,
proportions of non-PCV13 serotypes increased during the PCV13
era. In comparison, a relatively moderate decline in pneumococcal
carriage, featuring a substantial decrease of vaccine-serotypes and
concomitant increase of non-vaccine serotypes was observed in
the immediate period following PCV introduction in southern
Israel [25].
Within this study, we didn’t report any data on antimicrobial
resistance patterns as this has been recently addressed within
another study [14]. In brief, during 2004–2014, the proportion of
non-susceptible isolates significantly decreased for penicillin, cef-
triaxone, erythromycin and trimethoprim/sulfamethoxazole
(TMP-SMX). This is partly due to the decrease of more resistant
PCV13 serotypes (e.g. 6B, 9V, 14 and 19A) after the vaccine intro-
duction [14].
We have additionally analysed pneumococcal culture data of
MEF from patients with tympanic membrane perforation. Sponta-
neous perforation is a common complication reported among 15%
of AOM episodes and caused by the same bacteria as uncompli-
cated AOM [26,27], and a positive pneumococcal culture of >30%
has been described [27–29]. In our study we observed similar pro-
portions for pneumococcal carriage in the pre PCV7 era, but this
number decreased to 17% in the PCV13 era. In Israel, a near-
elimination of PCV13 serotypes in MEF has been described [5]. In
contrast, we observed a high proportion of serotype 3 (an addi-
tional PCV13 serotype) isolated from MEF even after the introduc-
tion of PCV13. This could explain why pneumococcal carriage
within MEF did not decrease as within NPS in our setting. Serotype
3 has also been described as most frequently isolated from patients
with OM in Germany [20]. It has been speculated that PCV13 trig-
gers only weak immune reactions to their serotype 3 components
[30–32]. Interestingly, pneumococcal culture results from MEF as
compared to the NPS showed striking similarities including a
decreasing trend on S. pneumoniae carriage after PCV13 introduc-
tion and similarities within the serotype epidemiology in our set-
ting. More specifically, an increase of the non PCV13 serogroups/
serotypes 11, 15 and 23 (excluding serotype 23F) was identified
within both, MEF and NPS.
This study has several strengths. First, this is a very large
surveillance-based study that included pneumococcal culture data
for both NPS and MEF from patients with AOM. Although this
surveillance network was initially composed of a convenience
sample of GP and paediatricians, representativeness for the Swiss
population has been approximated [15]. Second, the study dura-
tion was long and already starting three years before the introduc-
tion of PCV7 on a national level, making it one of only few studies
to investigate AOM episodes using MEF and NPS cultures over such
a long duration. Finally, the serotyping data is very detailed andavailable for both MEF and NPS, allowing concurrent analysis of
the serotype epidemiology.
There are also limitations to this study. First, sampling of the
NPS and/or MEF was not performed for all the patients with
AOM visiting the doctors of the network due to patients or doctors
not consenting to the sampling, which introduces a degree of
uncertainty in generalizability to the total Swiss population. How-
ever, distribution of gender, preceding antibiotic therapy, and AOM
history was evenly distributed for all the three eras. Second, our
sample of MEF only included AOM cases with spontaneous perfo-
ration, which might introduce an overrepresentation of severe
cases. Third, we did not collect any information re breastfeeding
for the very young AOM patients, smoking exposures, number of
siblings and/or presence/absence of infant influenza vaccination.
Fourth, we did not assess a potential association of the number
of AOM cases and regional variation in the vaccine coverage. This
would have been a complex analysis necessitating coverage data
from various regions during identical years, which was not avail-
able for this study. Finally, we did not assess for pneumococcal
co-colonisation and/or other otopathogens (e.g. non typeable Hae-
mophilus influenzae or Moraxella catarrhalis) but both issues have
been addressed by us and within other studies [33–37]. More pre-
cisely, the presence of other otopathogens has been investigated by
a non-culture approach, by 16S rRNA sequencing, allowing a whole
microbiota characterization [37].
In conclusion, the combination of a decreasing number of sam-
ples from patients with AOM within the surveillance network, an
increasing mean age of patients with AOM, and a substantial
decrease of serotypes included in the conjugate vaccines suggest
a considerable impact of the conjugate vaccines PCV7 and PCV13
on pneumococcal nasopharyngeal carriage and AOM incidence in
Switzerland. However, it remains to be determined if serotype
replacement poses a risk to undermine the effects of the vaccines
in the future.Funding
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